US4294829A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Powdery pharmaceutical composition and powdery preparation for application to the nasal mucosa, and method for administration thereof
Assignee: Teijin Ltd
•
Filing: 1980-07-30
•
Granted: 1981-10-13
•
Expires: 2000-07-30
Abstract
Abstract A powdery pharmaceutical composition and a powdery preparation in unit dosage form for application to the mucosa of the nasal cavity, at least about 90% of which consists of particles having an effective particle diameter of about 20 to about 250 microns, said composition comprising a lower alkyl ether of cellulose having a viscosity, determined at about 37° C. for a 2% aqueous solution thereof, of at least about 5 centipoises and a pharmaceutically effective amount of a drug; and a method for treating or preventing a human nasal disease, which comprises administering a powdery preparation in unit dosage form to the nasal cavity of a human being requiring treatment or prevention of a nasal disease through his nostrils.
Inventors
- 👤 Yoshiki Suzuki
- 👤 Hiroshi Ikura
- 👤 Gentaro Yamashita
- 👤 Tsuneji Nagai
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 11:11
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0043
Claims Analysis
Total Claims: 22
Claim 1
Independent Claim
131 words
A powdery pharmaceutical composition for application to the mucosa of the nasal cavity, at least about 90% of which consists of particles having an effective particle diameter of about 20 to about 250 microns, said composition comprising a lower alkyl ether of cellulose selected from the group consisting of methyl cellulose, hydroxy-lower alkyl cellulose and carboxylate formed between alkali metals and carboxy-lower alkyl cellulose wherein said lower alkyls have 2 or 3 carbon atoms, said lower alkyl ether of cellulose having a viscosity, determined at about 37° C. for a 2% aqueous solution thereof, of at least about 5 centipoises and a pharmaceutically effective amount of a drug selected from the group consisting of a steroidal anti-inflammatory agent, a nonsteroidal anti-inflammatory agent, an anti-histaminic agent, an anti-allergic agent and a vasoconstrictor.
Claim 2
Dependent Claim
131 words
A powdery pharmaceutical composition for application to the mucosa of the nasal cavity, at least about 90% of which consists of particles having an effective particle diameter of about 20 to about 250 microns, said composition comprising a lower alkyl ether of cellulose selected from the group consisting of methyl cellulose, hydroxy-lower alkyl cellulose and carboxylate formed between alkali metals and carboxy-lower alkyl cellulose wherein said lower alkyls have 2 or 3 carbon atoms, said lower alkyl ether of cellulose having a viscosity, determined at about 37° C. for a 2% aqueous solution thereof, of at least about 5 centipoises and a pharmaceutically effective amount of a drug selected from the group consisting of a steroidal anti-inflammatory agent, a nonsteroidal anti-inflammatory agent, an anti-histaminic agent, an anti-allergic agent and a vasoconstrictor.
Claim 3
Dependent Claim
27 words
The composition of claim 1 wherein said lower alkyl ether of cellulose is methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, carboxymethylhydroxyethyl cellulose or sodium carboxymethyl cellulose.
Claim 4
Dependent Claim
20 words
The composition of claim 1 wherein said lower alkyl ether of cellulose is methyl cellulose, hydroxypropyl cellulose or hydroxypropylmethyl cellulose.
Claim 5
Dependent Claim
15 words
The composition of claim 1 wherein said lower alkyl ether of cellulose is hydroxypropyl cellulose.
Claim 6
Dependent Claim
35 words
The composition of claim 1 wherein said lower alkyl ether of cellulose has a viscosity, determined at about 37° C. for a 2% by weight aqueous solution thereof, of about 5 to about 5000 centipoises.
Claim 7
Dependent Claim
28 words
The composition of claim 1 at least about 90% by weight of which consists of particles having an effective particle diameter of about 20 to about 150 microns.
Claim 8
Dependent Claim
56 words
The composition of claim 1 wherein said drug forms particles independent from particles of said cellulose ether, or adheres to the surface of the particles of said cellulose ether, or is dispersed as particles forming a discrete phase in the particles of said cellulose ether, or is intimately dispersed in the particles of said cellulose ether.
Claim 9
Dependent Claim
16 words
The composition of claim 1 wherein said steroidal anti-inflammatory agent is triamcinolone acetonide or beclomethasone dipropionate.
Claim 10
Dependent Claim
12 words
The composition of claim 1 wherein said nonsteroidal anti-inflammatory agent is indomethacine.
Claim 11
Dependent Claim
14 words
The composition of claim 1 wherein said antihistaminic agent is chloropheniramine maleate or clemastine.
Claim 12
Dependent Claim
14 words
The composition of claim 1 wherein said antiallergic agent is ephedrine or sodium cromoglycate.
Claim 13
Dependent Claim
11 words
The composition of claim 1 wherein said vasoconstrictor is naphazoline nitrate.
Claim 14
Dependent Claim
139 words
A powdery preparation in unit dosage form for application to the mucosa of the nasal cavity, at least about 90% by weight of which consists of particles having an effective particle diameter of about 20 to about 250 microns, said powdery preparation comprising a lower alkyl ether of cellulose selected from the group consisting of methyl cellulose, hydroxy-lower alkyl cellulose and carboxylate formed between alkali metals and carboxy-lower alkyl cellulose wherein said lower alkyls have 2 or 3 carbon atoms, said lower alkyl ether of cellulose having a viscosity, determined at about 37° C. for a 2% by weight aqueous solution thereof, of at least about 5 centipoises and a pharmaceutically effective amount of a drug selected from the group consisting of a steroidal anti-inflammatory agent, a nonsteroidal anti-inflammatory agent, an anti-histaminic agent, an anti-allergic agent and a vasoconstrictor.
Claim 15
Dependent Claim
139 words
A powdery preparation in unit dosage form for application to the mucosa of the nasal cavity, at least about 90% by weight of which consists of particles having an effective particle diameter of about 20 to about 250 microns, said powdery preparation comprising a lower alkyl ether of cellulose selected from the group consisting of methyl cellulose, hydroxy-lower alkyl cellulose and carboxylate formed between alkali metals and carboxy-lower alkyl cellulose wherein said lower alkyls have 2 or 3 carbon atoms, said lower alkyl ether of cellulose having a viscosity, determined at about 37° C. for a 2% by weight aqueous solution thereof, of at least about 5 centipoises and a pharmaceutically effective amount of a drug selected from the group consisting of a steroidal anti-inflammatory agent, a nonsteroidal anti-inflammatory agent, an anti-histaminic agent, an anti-allergic agent and a vasoconstrictor.
Claim 16
Dependent Claim
33 words
The powdery preparation of claim 13 wherein said drug is a steroidal anti-inflammatory agent in an amount of about 0.005 to about 1% by weight based on the weight of the powdery preparation.
Claim 17
Dependent Claim
32 words
The powdery preparation of claim 13 wherein said drug is an anti-histaminic agent in an amount of about 0.1 to about 20% by weight based on the weight of the powdery preparation.
Claim 18
Dependent Claim
17 words
The powdery preparation of any one of claims 13 to 15 which is filled in a capsule.
Claim 19
Dependent Claim
14 words
The capsule preparation of claim 16 wherein said capsule is a hard gelatin capsule.
Claim 20
Independent Claim
179 words
A method for treating for preventing a human nasal disease, which comprises administering a powdery preparation in unit dosage form to the nasal cavity of a human being requiring treatment or preventing of a nasal disease through his nostrils, thereby adhering said powdery preparation to the nasal mucosa, said powdery preparation comprising a lower alkyl ether of cellulose selected from the group consisting of methyl cellulose, hydroxy-lower alkyl cellulose and carboxylate formed between alkali metals and carboxy-lower alkyl cellulose wherein said lower alkyls have 2 or 3 carbon atoms, said lower alkyl ether of cellulose having a viscosity, determined at about 37° C. for a 2% by weight aqueous solution thereof, of at least about 5 centipoises and a pharmaceutically effective amount of an agent for treating or preventing the nasal disease selected from the group consisting of a steroidal anti-inflammatory agent, a nonsteroidal anti-inflammatory agent, an anti-histaminic agent, an anti-allergic agent and a vasoconstrictor, at least about 90% by weight of said preparation consisting of particles having an effective particle diameter of about 20 to about 250 microns.
Claim 21
Independent Claim
179 words
A method for treating for preventing a human nasal disease, which comprises administering a powdery preparation in unit dosage form to the nasal cavity of a human being requiring treatment or preventing of a nasal disease through his nostrils, thereby adhering said powdery preparation to the nasal mucosa, said powdery preparation comprising a lower alkyl ether of cellulose selected from the group consisting of methyl cellulose, hydroxy-lower alkyl cellulose and carboxylate formed between alkali metals and carboxy-lower alkyl cellulose wherein said lower alkyls have 2 or 3 carbon atoms, said lower alkyl ether of cellulose having a viscosity, determined at about 37° C. for a 2% by weight aqueous solution thereof, of at least about 5 centipoises and a pharmaceutically effective amount of an agent for treating or preventing the nasal disease selected from the group consisting of a steroidal anti-inflammatory agent, a nonsteroidal anti-inflammatory agent, an anti-histaminic agent, an anti-allergic agent and a vasoconstrictor, at least about 90% by weight of said preparation consisting of particles having an effective particle diameter of about 20 to about 250 microns.
Claim 22
Dependent Claim
20 words
The method of claim 18 wherein the administration of said powdery preparation to the nasal cavity is performed by spraying.
References Cited (Backward Citations)
US4013792A
Cited
US4225597A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-10-12 | 1985-04-13 | 1985-10-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-10-12 | 1989-04-13 | 1989-10-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-10-12 | 1993-04-13 | 1993-10-13 | $7700.00 | Window Closed / Lapsed |